Appropriate elicitation of patients’ preferences for treatment and involving patients in the shared decision-making (SDM) process can improve disease management and patient adherence. Especially, in the management of non-urgent and non-fatal diseases, such as OA. The assessment of patients’ preferences is a crucial aspect of healthcare systems worldwide. Due to the long-term use of the pharmacological treatment and the adverse effects, surgical interventions such as joint replacement may be considered the last option. The treatment for OA includes non-pharmacological and pharmacological options, which focus on alleviating pain and stiffness and limiting functional loss.
Osteoarthritis (OA) is a highly prevalent chronic joint disease, affecting 7% of the world population. OA patients also prefer prescribed medications to internet-purchased and over-the-counter options. Although the “Way of taking medicine” was the least important attribute it was associated with the highest variation amongst patients. ConclusionsĪrab OA patients are similar to other ethnic groups in trading-off benefits and side effects and consistently prioritizing the avoidance of medications’ side effects. The “way of taking the medicine” attribute had the highest coefficient of variation (70%) and the four side effect attributes “risk of gastric ulcer, addiction, kidney and liver impairment, and heart attacks and strokes” had a coefficient of variation from 18 to 21%. The avoidance of medication’s side effects accounted for 66% relative importance compared to 6% relative importance for the medication’s benefits. Study participants were 1030 OA patients, 83.6% aged 50 or older and 83.4% female.
Results were standardized using Z-score via SPSS. The questionnaire was developed using Sawtooth Software and analyzed through Hierarchical Bayesian (HB). MethodsĪ United Arab Emirates (UAE) based Patient and Public Involvement (PPI) group designed the ACBC questionnaire with 10 attributes and 34 levels.
To assess osteoarthritis (OA) patients’ preferences for pharmaceutical treatment via Adaptive Choice-Based Conjoint (ACBC) method.
0 kommentar(er)
